Results 111 to 120 of about 1,029,564 (269)

The Role of Chemotherapy in Pediatric Myoepithelial Carcinoma: A Systematic Review of the Literature

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Myoepithelial carcinoma (MEC) in pediatric patients is a rare and aggressive malignancy characterized by heterogeneous morphology and variable molecular features. The optimal role of chemotherapy remains unclear. We conducted a systematic review according to PRISMA 2020 guidelines to evaluate chemotherapy in pediatric and young‐adult patients ...
Marco Salvi   +7 more
wiley   +1 more source

Growth and Development among Patients with Pierre Robin Sequence: National Center for Child Health and Development (Tokyo, Japan) Experience

open access: yesPlastic and Reconstructive Surgery, Global Open, 2021
Makoto Hikosaka, MD   +4 more
doaj   +1 more source

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas   +3 more
wiley   +1 more source

Nephrogenic Rests/Nephroblastomatosis in Patients With Unilateral Wilms Tumor Are Not Associated With an Increased Risk of Relapse: An Analysis of Patients Treated on the SIOP‐WT‐2001 Protocol in the SIOP‐UK‐CCLG and SIOP‐GPOH Studies (2001–2022)

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Nephrogenic rests (NRs) and nephroblastomatosis (NBM) are precursor lesions for development of Wilms tumor (WT). Their association with the risk of relapse has not been properly assessed, partly due to misunderstanding of their diagnostic criteria and terminology.
Gordan M. Vujanić   +5 more
wiley   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley   +6 more
wiley   +1 more source

Evaluating the Readability of Patient‐Facing Online Educational Materials for Pediatric Leukemia and Lymphoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Together, leukemia and lymphoma account for 38.7% of newly diagnosed pediatric cancer cases in the United States each year. Many caregivers utilize online resources to inform medical health decisions. Understanding the readability of these materials is critical to ensuring comprehensible patient education.
Chloe Strege   +6 more
wiley   +1 more source

Paternal perinatal mental health and early child development: An outcome-wide analysis. [PDF]

open access: yesInfant Ment Health J
Scarlett H   +6 more
europepmc   +1 more source

Improvement of Sickle Cell Disease Care Mitigates the Healthcare Utilization Induced by Increased Prevalence: Experience of a Tertiary Pediatric Center

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Sickle cell disease (SCD) has undergone major changes in the last decades. Its prevalence has been steadily increasing and numerous advances have been made in the management of the disease. However, the effect in real‐life setting of these major changes is unknown, particularly in a Canadian environment. Procedure We aimed to assess
Maude Cigna   +16 more
wiley   +1 more source

Organoids in pediatric cancer research

open access: yesFEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Home - About - Disclaimer - Privacy